Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America's IDWeek 2024 annual meeting in Los Angeles, California, from October 16-19, 2024. Thomas Triomphe Executive Vice President, Vaccines, Sanofi "The data featured at IDW ...